Coronary heart disease is the leading cause of death in the U.S., and patients who survive a coronary artery occlusion have a high risk for cardiac arrhythmias and sudden cardiac death. Spatial heterogeneity of sympathetic transmission is a major contributor to post-infarct arrhythmias and sudden cardiac death after myocardial infarction (MI), and sympathetic denervation predicted arrhythmia risk in recent human studies. We have identified two distinct types of sympathetic denervation after MI: 1) persistent denervation of the infarct/scar and adjacent border zone myocytes, and 2) transient denervation of uninjured peri-infarct myocardium. This proposal will develop methods to prevent or reverse both types of denervation, and determine if restoring sympathetic innervation throughout the ventricle decreases arrhythmia susceptibility. The infarct remains denervated after MI due to chondroitin sulfate proteoglycans (CSPGs). We identified protein tyrosine phosphatase receptor sigma (PTP?as the major CSPG receptor in sympathetic neurons, and found that removing PTP?esulted in reinnervation of the border zone and hyperinnervation of the cardiac scar. Preliminary data suggest that eliminating PTP?ormalizes cardiac electrophysiology and renders hearts surprisingly resistant to post-MI arrhythmias. This suggests that restoring sympathetic innervation has a beneficial effect on arrhythmia susceptibility. However, it's not clear if re-innervation is the key to preventing arrhythmias, or if other actions of PTP?ontribut to decreased arrhythmia susceptibility in PTP?- hearts. We hypothesize that the major action of PTP?s to prevent reinnervation via interactions with CSPGs (Aim 1), and that restoring sympathetic innervation will decrease arrhythmia susceptibility (Aim 2). Peri-infarct myocardium is transiently denervated 1 and 3 days after MI and loss of sympathetic fibers outside the infarct requires activation of the p75 neurotrophin receptor. We identified ProNGF and a form of Brain Derived Neurotrophic Factor (either proBDNF or BDNF) as p75 ligands that are elevated in the heart after MI. We will test the hypothesis that pro-neurotrophins and/or BDNF stimulate peri-infarct denervation, and that preventing peri- infarct denervation will decrease arrhythmia susceptibility (Aim 3). We have assembled an outstanding team of experts along with unique animal models and novel genetic tools to assist us in completing these studies. This work will test directly if manipulating cardiac nerves after MI can normalize cardiac electrophysiology and decrease arrhythmia frequency, opening a new avenue for therapeutic development.

Public Health Relevance

Coronary heart disease is the leading cause of death in the U.S, and patients have a high risk for cardiac arrhythmias after surviving a myocardial infarction (heart attack). Spatial heterogeneity of sympathetic nerves, including denervation, is a major contributor to post-infarct cardiac arrhythmias. These studies will determine if preventing denervation or restoring nerve regeneration decreases arrhythmia susceptibility. This will have important implications for the treatment of patients after myocardial infarction.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL093056-08
Application #
9173035
Study Section
Clinical Neuroplasticity and Neurotransmitters Study Section (CNNT)
Program Officer
Lathrop, David A
Project Start
2008-07-01
Project End
2018-10-31
Budget Start
2016-11-01
Budget End
2017-10-31
Support Year
8
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Physiology
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Li, Bingbing X; Gardner, Ryan; Xue, Changhui et al. (2016) Systemic Inhibition of CREB is Well-tolerated in vivo. Sci Rep 6:34513
Courter, Lauren A; Shaffo, Frances C; Ghogha, Atefeh et al. (2016) BMP7-induced dendritic growth in sympathetic neurons requires p75(NTR) signaling. Dev Neurobiol 76:1003-13
Ajijola, Olujimi A; Shivkumar, Kalyanam; Habecker, Beth A (2016) Natriuretic peptides and peripheral autonomic neurotransmission: back to the A, B, and C's. Cardiovasc Res 112:619-621
Gardner, Ryan T; Ripplinger, Crystal M; Myles, Rachel C et al. (2016) Molecular Mechanisms of Sympathetic Remodeling and Arrhythmias. Circ Arrhythm Electrophysiol 9:e001359
Johnsen, Dustin; Olivas, Antoinette; Lang, Bradley et al. (2016) Disrupting protein tyrosine phosphatase σ does not prevent sympathetic axonal dieback following myocardial infarction. Exp Neurol 276:1-4
Habecker, Beth A; Anderson, Mark E; Birren, Susan J et al. (2016) Molecular and cellular neurocardiology: development, and cellular and molecular adaptations to heart disease. J Physiol 594:3853-75
Gardner, R T; Wang, L; Lang, B T et al. (2015) Targeting protein tyrosine phosphatase ýý after myocardial infarction restores cardiac sympathetic innervation and prevents arrhythmias. Nat Commun 6:6235
Jones, Casey M; Baker-Groberg, Sandra M; Cianchetti, Flor A et al. (2014) Measurement science in the circulatory system. Cell Mol Bioeng 7:1-14
Pellegrino, Michael J; Habecker, Beth A (2013) STAT3 integrates cytokine and neurotrophin signals to promote sympathetic axon regeneration. Mol Cell Neurosci 56:272-82
Gardner, Ryan T; Habecker, Beth A (2013) Infarct-derived chondroitin sulfate proteoglycans prevent sympathetic reinnervation after cardiac ischemia-reperfusion injury. J Neurosci 33:7175-83

Showing the most recent 10 out of 17 publications